Cullinan Therapeutics Zipalertinib Combo Clears Key Phase 3 Hurdle As First-Line Lung Cancer Treatment Option Takes Shape

Key takeaways

• Cullinan Therapeutics' zipalertinib combo cleared a key Phase 3 hurdle, showing strong efficacy and tolerability in a first-line lung cancer treatment option.
• 35% confirmed objective response rate (ORR)
• 8.8 months median duration of response (mDOR)
• 285 adults enrolled in the REZILIENT3 trial

What happened

Cullinan Therapeutics' zipalertinib combo cleared a key Phase 3 hurdle as a first-line lung cancer treatment option takes shape.

Why it matters

The combo showed strong efficacy and tolerability in a Phase 3 trial, outperforming Johnson & Johnson's Rybrevant plus chemotherapy in the first-line setting. This could make zipalertinib a viable treatment option for patients with NSCLC and EGFR exon 20 insertion mutations. The FDA has accepted a New Drug…

Short-term and longer-term

Short-term. Cullinan Therapeutics' shares were up 1.79% at $19.95 at the time of publication on Thursday.

Longer-term. The zipalertinib combo's strong efficacy and tolerability in the first-line setting could make it a viable treatment option for patients with NSCLC and EGFR exon 20 insertion mutations.